Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $158.34B · View financials
Snapshot Sep 9, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: PFE stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Implied fair value · at PFE's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 71% equity / 29% debt · EV / Revenue 3.55x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
Bear
$12.82
Base
$16.23
Bull
$22.30
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JOHNSON & JOHNSON
PFE vs JNJ
Merck & Co., Inc.
PFE vs MRK
AbbVie Inc.
PFE vs ABBV
BRISTOL MYERS SQUIBB CO
PFE vs BMY
ELI LILLY & Co
PFE vs LLY
AMGEN INC
PFE vs AMGN
THERMO FISHER SCIENTIFIC INC.
PFE vs TMO
AGILENT TECHNOLOGIES, INC.
PFE vs A
DANAHER CORP /DE/
PFE vs DHR
BIO-RAD LABORATORIES, INC.
PFE vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
PFE vs PACB
Natera, Inc.
PFE vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PFE can stabilize revenue and improve quality metrics without a major increase in leverage, then the stock looks attractive versus the ILMN-based ILMN valuation because it trades at much lower P/E, P/S, EV/EBITDA, and EV/Revenue multiples.
ILMN-implied value of $51.18 suggests a 104.6% upside from PFE's current price of $25.01, but that gap is driven by ILMN's much higher trading multiples rather than clear operational superiority across every metric. PFE is closer to its historical and DCF bands, which indicates the market is not fully assigning ILMN multiple framework to its current fundamentals.
Supporting Metrics
